AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22434343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic menthol stimulation at concentrations of 0.8, 1.5, and 3.4 μg/mL
Number of subjects: 20
Study 22434343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine stimuli at concentrations of 99 and 134 ng/mL
Number of subjects: 20
Study 22434343 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol stimuli combined with low-intensity nicotine stimuli
Number of subjects: 20
Study 22434343 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol stimuli combined with high-intensity nicotine stimuli
Number of subjects: 20
Study 22434343 — intervention group
Group type: COMPARATOR
Intervention: No menthol (placebo control)
Number of subjects: 20
Study 20849495 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 108
Study 20849495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 108
Study 20849495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Droperidol and Ondansetron
Number of subjects: 108
Study 20849495 — intervention group
Group type: COMPARATOR
Intervention: Neither
Number of subjects: 108
Study 17597523 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological, family-based intervention consisting of three sessions delivered by a health psychologist, including home visits and a follow-up telephone call.
Number of subjects: 122
Study 17597523 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 122
Study 14678066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge, 2 mg or 4 mg
Number of subjects: 1818
Study 14678066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1818
Study 10946984 — intervention group
Group type: EXPERIMENTAL
Intervention: PuriLens System
Number of subjects: 80
Study 10946984 — intervention group
Group type: COMPARATOR
Intervention: ReNu, Bausch & Lomb (Control)
Number of subjects: 80
Study 10452011 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group (EF group)
Number of subjects: 21
Study 10452011 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding group (DF group)
Number of subjects: 21
Study 1543325 — intervention group
Group type: EXPERIMENTAL
Intervention: Saptamrita Lauha
Number of subjects: 48
Study 1543325 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 3839157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Adriamycin (doxorubicin), and 5-fluorouracil (CAF)
Number of subjects: 162
Study 3827157 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (mean dose = 235 +/- 47.5 mg/day)
Number of subjects: 32
Study 3827157 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 30670276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 184
Study 30670276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with rose essential oil
Number of subjects: 184
Study 30670276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with ginger essential oil
Number of subjects: 184
Study 30670276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure water)
Number of subjects: 184
Study 30670276 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (lavender, rose, ginger, placebo)
Number of subjects: 184
Study 26869339 — intervention group
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture (BFA) protocol, eight-week once weekly ten-needle treatment (n=13)
Number of subjects: 24
Study 26869339 — intervention group
Group type: COMPARATOR
Intervention: Delayed entry group (waiting list followed by BFA protocol, n=11)
Number of subjects: 24
Study 26869339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BFA and control)
Number of subjects: 24
Study 26869339 — intervention group
Group type: COMPARATOR
Intervention: BFA group vs. control group
Number of subjects: 24
Study 26691209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for 28 days)
Number of subjects: 1053
Study 26691209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times per day for 28 days)
Number of subjects: 1053
Study 26691209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in combination with prednisolone)
Number of subjects: 1053
Study 26691209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in combination with pentoxifylline)
Number of subjects: 1053
Study 26691209 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes at 90 days and 1 year
Number of subjects: 1053
Study 23748990 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving for parents with neurodegenerative diseases (Alzheimer's or Parkinson's)
Number of subjects: 34
Study 21398006 — intervention group
Group type: EXPERIMENTAL
Intervention: SaliCept patch
Number of subjects: 104
Study 21398006 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvogyl
Number of subjects: 104
Study 21398006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (808 nm, 100 mW, 60 seconds, 7.64 J/cm²)
Number of subjects: 104
Study 21398006 — intervention group
Group type: COMPARATOR
Intervention: Curettage and irrigation alone
Number of subjects: 104
Study 18482079 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level site-based intervention including on-site HIV testing, condom promotion, and peer education.
Number of subjects: 147
Study 18482079 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no intervention).
Number of subjects: 147
Study 17074107 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/d plus 5-aminosalicylic acid (5-ASA) 2 g/d
Number of subjects: 42
Study 17074107 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA) or sulfasalazine alone
Number of subjects: 42
Study 12736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (300 mg/m(2), i.v., day 1) and cisplatin (100 mg/m(2), i.v., day 2)
Number of subjects: 253
Study 12736113 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (600 mg/m(2), i.v., day 1) and cisplatin (100 mg/m(2), i.v., day 2)
Number of subjects: 253
Study 12736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum dose-intensified arm
Number of subjects: 253
Study 12736113 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 253
Study 10672632 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12
Study 10672632 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 12
Study 10672632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9315595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen, 0.625 mg/day
Number of subjects: 0
Study 9315595 — intervention group
Group type: COMPARATOR
Intervention: Drug-free period
Number of subjects: 0
Study 8327621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation on relevant speaker
Number of subjects: 0
Study 8327621 — intervention group
Group type: COMPARATOR
Intervention: Fixation on irrelevant speaker
Number of subjects: 0
Study 8327621 — intervention group
Group type: COMPARATOR
Intervention: Central fixation
Number of subjects: 0
Study 3777829 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin plus metronidazole (administered for one day)
Number of subjects: 100
Study 3777829 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (administered for five days)
Number of subjects: 100
Study 28976844 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at site X (over the root apex)
Number of subjects: 120
Study 28976844 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at site Y (over the midpoint)
Number of subjects: 120
Study 28976844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity cutting procedures
Number of subjects: 120
Study 28976844 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep caries group
Number of subjects: 120
Study 26892211 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered two percent lidocaine
Number of subjects: 30
Study 26892211 — intervention group
Group type: COMPARATOR
Intervention: Two percent lidocaine with 1:200,000 epinephrine
Number of subjects: 30
Study 23687948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart with NPH insulin
Number of subjects: 350
Study 23687948 — intervention group
Group type: COMPARATOR
Intervention: Human insulin with NPH insulin
Number of subjects: 350
Study 22752628 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT (Goldmann applanation tonometry)
Number of subjects: 60
Study 22752628 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT (Dynamic contour tonometry)
Number of subjects: 60
Study 22752628 — intervention group
Group type: EXPERIMENTAL
Intervention: iCare
Number of subjects: 60
Study 22752628 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPen
Number of subjects: 60
Study 21163074 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + DDP
Number of subjects: 90
Study 21163074 — intervention group
Group type: COMPARATOR
Intervention: DDP + 5‐Fu
Number of subjects: 90
Study 18950853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 203
Study 18950853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 203
Study 18950853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 1.0 mg
Number of subjects: 203
Study 18950853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 16648042 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-like chemotherapy plus rituximab (n=413)
Number of subjects: 824
Study 16648042 — intervention group
Group type: COMPARATOR
Intervention: CHOP-like chemotherapy alone (n=411)
Number of subjects: 824
Study 16648042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 824
Study 12793557 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 370
Study 12793557 — intervention group
Group type: COMPARATOR
Intervention: Functional treatment
Number of subjects: 370
Study 10915096 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 494
Study 10915096 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (adjusted for CD4 T cell count, race or ethnicity, injection drug use, and age)
Number of subjects: 494
Study 10915096 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 494
Study 9816176 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate with overlapping cytarabine, n = 69
Number of subjects: 140
Study 9816176 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone, n = 71
Number of subjects: 140
Study 9816176 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate/cytarabine infusions, n = 69 (low-risk) and n = 248 (all risk groups)
Number of subjects: 140
Study 1432498 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery as per the rigid protocol in the Prism Adaptation Study (PAS)
Number of subjects: 322
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: P3-latency increase of 0.92 ms/year (280 ms at age 20)
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: P3-amplitude decrease of 0.14 microV/year (17.2 microV at age 20)
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: P2-wave amplitude (12.8 ms at age 20) not influenced by age
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: P2-wave latency (160 ms at age 20) not influenced by age
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: Females show greater amplitudes of P2- and P3-components
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: P3-latency increase in females is 0.25 ms/year (starting with 296 ms at age 20)
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: P3-latency increase in males is 1.3 ms/year (starting with 272 ms at age 20)
Number of subjects: 54
Study 3933959 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 'eyes open' or 'eyes closed' did not influence late auditory evoked potentials
Number of subjects: 54
Study 31003798 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐ionto CXL
Number of subjects: 34
Study 31003798 — intervention group
Group type: COMPARATOR
Intervention: Standard CXL
Number of subjects: 34
Study 31003798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 29993449 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG detector
Number of subjects: 30
Study 29993449 — intervention group
Group type: COMPARATOR
Intervention: EEG-BCI
Number of subjects: 30
Study 26526160 — intervention group
Group type: EXPERIMENTAL
Intervention: PULSE Program (self-administered lifestyle intervention)
Number of subjects: 101
Study 26526160 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no intervention)
Number of subjects: 101
Study 24245566 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus renal-artery stenting
Number of subjects: 947
Study 24245566 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 947
Study 22722513 — intervention group
Group type: EXPERIMENTAL
Intervention: Early switch strategy with duloxetine 60 to 120 mg/d for 12 weeks
Number of subjects: 566
Study 22722513 — intervention group
Group type: COMPARATOR
Intervention: Conventional switch strategy (4 further weeks on escitalopram 10 to 20 mg/d, then switch to duloxetine if nonresponse)
Number of subjects: 566
Study 19462249 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 11
Study 19462249 — intervention group
Group type: EXPERIMENTAL
Intervention: Themes related to breastfeeding experiences
Number of subjects: 11
Study 19462249 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for improved support
Number of subjects: 11
Study 17261285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg ethinyl‐E(2) (EE) three times a day for 2 weeks
Number of subjects: 50
Study 17261285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15371787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 42
Study 15371787 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 42
Study 11345387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 mg/kg) plus four additional intravenous doses over 24 h
Number of subjects: 246
Study 11345387 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 246
Study 9817260 — intervention group
Group type: EXPERIMENTAL
Intervention: Whipple origami exercise (20 minutes)
Number of subjects: 37
Study 9817260 — intervention group
Group type: COMPARATOR
Intervention: Commercially available teaching video (18 minutes)
Number of subjects: 37
Study 9817260 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttest after both exercises
Number of subjects: 37
Study 9817260 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttest after first exercise
Number of subjects: 37
Study 7826049 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly polished fingernails
Number of subjects: 102
Study 7826049 — intervention group
Group type: EXPERIMENTAL
Intervention: Chipped fingernail polish
Number of subjects: 102
Study 7826049 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural, polish-free fingernails
Number of subjects: 102
Study 3071617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) single administration
Number of subjects: 73
Study 3071617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) + Fosfomycin (FOM) administration
Number of subjects: 73
Study 31983281 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day AXOS for 12 weeks
Number of subjects: 48
Study 31983281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 12 weeks
Number of subjects: 48
Study 29968371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy (MGT)
Number of subjects: 215
Study 29968371 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 215
Study 29180593 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescriptions
Number of subjects: 20
Study 29180593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help treatments (including painkillers)
Number of subjects: 20
Study 29180593 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam inhalation
Number of subjects: 20
Study 27045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) + group cognitive behavioral therapy (gCBT)
Number of subjects: 96
Study 27045520 — intervention group
Group type: COMPARATOR
Intervention: Befriending + group cognitive behavioral therapy (gCBT)
Number of subjects: 96
Study 24740713 — intervention group
Group type: EXPERIMENTAL
Intervention: T2‐4 sympathectomy treatment
Number of subjects: 116
Study 24740713 — intervention group
Group type: COMPARATOR
Intervention: T3‐4 sympathectomy treatment
Number of subjects: 116
Study 24740713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 21899916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 98
Study 21899916 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 98
Study 21899916 — intervention group
Group type: COMPARATOR
Intervention: Non-CAD group
Number of subjects: 98
Study 21899916 — intervention group
Group type: COMPARATOR
Intervention: CAD group
Number of subjects: 98
Study 19351723 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 25
Study 19351723 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 25
Study 19351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal and pulsatile GH secretion
Number of subjects: 25
Study 19351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal visceral fat
Number of subjects: 25
Study 19351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting IGF-I concentration
Number of subjects: 25
Study 19351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated pulsatile GH secretion
Number of subjects: 25
Study 17448723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 17448723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15204282 — intervention group
Group type: EXPERIMENTAL
Intervention: Link format (plain text, underlined, bold, or bold and underlined)
Number of subjects: 0
Study 15204282 — intervention group
Group type: EXPERIMENTAL
Intervention: Link format (bold and underlined)
Number of subjects: 0
Study 11774112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential vitamin B6 (100 mg/d for CRI, 200 mg/d for HD) and folic acid (5 mg/d) supplementation for more than 3 months
Number of subjects: 44
Study 11774112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential vitamin B6 and folic acid supplementation
Number of subjects: 44
Study 11774112 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 44
Study 11774112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation
Number of subjects: 44
Study 11774112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 treatment
Number of subjects: 44
Study 9519774 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaziquone and mitoxantrone
Number of subjects: 167
Study 9519774 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone and etoposide
Number of subjects: 167
Study 9519774 — intervention group
Group type: COMPARATOR
Intervention: Diaziquone and etoposide
Number of subjects: 167
Study 9519774 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone/etoposide
Number of subjects: 167
Study 9519774 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaziquone arms
Number of subjects: 167
Study 9260074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine HCl (100 mg)
Number of subjects: 19
Study 9260074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use (as indicated by urine specimens)
Number of subjects: 19
Study 9260074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1674294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg body weight daily; n = 226)
Number of subjects: 456
Study 1674294 — intervention group
Group type: COMPARATOR
Intervention: Controlled-protein diet (1.0 g/kg daily; n = 230)
Number of subjects: 456
Study 1674294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group A
Number of subjects: 456
Study 1674294 — intervention group
Group type: COMPARATOR
Intervention: Controlled-protein diet (1.0 g/kg daily; n = 230) in group A
Number of subjects: 456
Study 1674294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group B
Number of subjects: 456
Study 1674294 — intervention group
Group type: COMPARATOR
Intervention: Controlled-protein diet (1.0 g/kg daily; n = 230) in group B
Number of subjects: 456
Study 1674294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group C
Number of subjects: 456
Study 1674294 — intervention group
Group type: COMPARATOR
Intervention: Controlled-protein diet (1.0 g/kg daily; n = 230) in group C
Number of subjects: 456
Study 7022214 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance doses of vinblastine
Number of subjects: 171
Study 7022214 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 171
Study 7022214 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall relapse rate
Number of subjects: 171
Study 30821121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with pediatric flexible fibreoptic bronchoscopy (BAL/FB)
Number of subjects: 42
Study 30821121 — intervention group
Group type: COMPARATOR
Intervention: Control group (general pneumonia patients)
Number of subjects: 42
Study 28248871 — intervention group
Group type: EXPERIMENTAL
Intervention: Centiderm
Number of subjects: 75
Study 28248871 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 75